0

Close
 
2022
Aneurysmal Subarachnoid Hemorrhage Drugs Market

Aneurysmal Subarachnoid Hemorrhage Drugs Market

by Drug Class (Opioid Analgesic, Calcium Channel Blocker, Anticonvulsant, Stool Softener, Osmotic Agents/Diuretics, Other Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2030
Update Available On-Demand

LS : Pharmaceuticals
✷  Report Code: A04249
Mar 2022 | Pages: 180
Tables: 90
Charts: 51

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

The global aneurysmal subarachnoid hemorrhage drugs market size was valued at $323.51 million in 2020, and is projected to reach $456.31 million by 2030, growing at a CAGR of 3.6% from 2021 to 2030. Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening type of stroke caused by bleeding in the area around the brain. The major factors that drive the growth of the global aSAH drugs market include surge in geriatric population and increase in population suffering from hypertension. Furthermore, lifestyle changes such as alcohol consumption and smoking increase risk of aSAH, which, in turn, propel the market growth.

The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the globe. The disease has forced a number of industries to shut their operations temporarily, including several sub-domains of healthcare. The COVID-19 pandemic led to disruptions in healthcare facilities. COVID-19 pandemic positively impacted key players in aSAH drugs market. Hemorrhagic cerebrovascular events, either due to aneurysmal rupture or spontaneous subarachnoid hemorrhage (SAH), are not rare in COVID-19. Several mechanisms such as coagulopathy, cytokine storm, viral endotheliopathy, hypertension, and immune modulation might play a role in the pathogenesis of SAH in COVID-19. Furthermore, during lockdown, patients faced difficulties with their ongoing treatment. However, community-dwelling individuals with disability were given special permission to go out for physical therapy and rehabilitation services. Moreover, patients suffering from aSAH had to switch to tele-medicine during the lockdown as they could not visit the hospitals.

Hypertension is one of the major factors that can lead to aSAH. As per the Centers for Disease Control and Prevention, about 70.0 million American adults suffer from high blood pressure, of which the condition of only 52.0% is under control. Moreover, according to the Centers for Medicare and Medicaid Services the U.S. healthcare expenditures grew from 4.6% to $3.8 trillion in 2019 and accounted for 17.7% of gross domestic product (GDP). In addition, the federal government accounted for 29 % of total health expenditures, followed by households with 28.4%. State and local governments accounted for 16.1% of total health care expenditures, while other private revenues accounted for 7.5%.

Furthermore, incidence of high blood pressure has increased, costing the U.S. $46.0 billion annually, which include the cost of healthcare services, medications to treat high blood pressure, and missed days of work.

In addition, increase in prevalence diseases such as stroke and hypertension and surge in geriatric population drive the growth of the aSAH drugs market. In addition, lifestyle changes, including increase in alcohol consumption and smoking rise the risk for aSAH, which, in turn, stimulates the market growth.

However, the associated side effects of drugs and medication taken during the treatment of aSAH restrain the aSAH drugs market share.

The aSAH drugs market is segmented on the basis of drug class and region. On the basis of drug class, the market is classified into opioid analgesic, calcium channel blocker, anticonvulsants, stool softeners, osmotic agents/diuretics, and other drugs. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA

Aneurysmal Subarachnoid Hemorrhage Drugs Market

Depending on drug class, the calcium channel blocker segment dominated the market and is expected to continue this trend during the forecast period, owing to increasing prevalence rate of cardiovascular diseases, changing lifestyle and hypertension. Rising assistance to people with anxiety disorders or bipolar disorder is also expected to help in the growth of the aneurysmal subarachnoid hemorrhage drugs market. In addition, increase patient awareness level, availability of the treatment options and vulnerable geriatric population are some of the influencing factors propelling the growth of the calcium channel blocker aSAH drugs market growth.

Aneurysmal Subarachnoid Hemorrhage Drugs Market

Region wise, North America dominated the market in 2020, owing to favorable healthcare infrastructure, which facilitated access to advanced aSAH drugs. In addition, government initiatives, including the Precision Medicine and Affordable Care Act, along with well-planned reimbursement policies, contributed to the market growth in North America. Moreover, surge in awareness among people and high purchasing parity resulted in increased demand for these devices. However, Asia-Pacific is expected to witness considerable market growth during the forecast period, due to rise in government support to enhance healthcare infrastructure. Economic developments in countries, including India and China, with higher disposable incomes fuel the demand for product. Moreover, China is expected to grow at high CAGR in, thereby making Asia-Pacific a aSAH drugs market opportunity.

The major companies profiled in this report include Azurity Pharmaceuticals, Johnson & Johnson, MediCure, NeurOp, Orexo AB, Pfizer, Inc., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vitrais, Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current aSAH drugs market trends, estimations, and dynamics of the aneurysmal subarachnoid hemorrhage drugs market analysis from 2020 to 2030 to identify the prevailing aneurysmal subarachnoid hemorrhage drugs market opportunities.
  • The aSAH Drugs Market analysis research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the aneurysmal subarachnoid hemorrhage drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global aSAH drugs industry trends, key players, market segments, application areas, and market growth strategies.

 Aneurysmal Subarachnoid Hemorrhage Drugs Market Report Highlights

Aspects Details
By Drug Class
  • Calcium Channel Blocker
  • Anticonvulsant
  • Stool Softener
  • Osmotic Agents/Diuretics
  • Other Drugs
  • Opioid Analgesic
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, United Kingdom, Italy, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Turkey, South Africa, Rest of LAMEA)
Key Market Players teva pharmaceutical industries ltd., orexo ab, Azurity Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Vitrais, Inc, medicure, Pfizer, Inc., NeurOp, Johnson and Johnson, Pharmaxis, Ltd.
 

  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Opioid Analgesic

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

    • 4.3 Calcium Channel Blocker

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

    • 4.4 Anticonvulsant

      • 4.4.1 Key market trends, growth factors and opportunities

      • 4.4.2 Market size and forecast, by region

      • 4.4.3 Market analysis by country

    • 4.5 Stool Softener

      • 4.5.1 Key market trends, growth factors and opportunities

      • 4.5.2 Market size and forecast, by region

      • 4.5.3 Market analysis by country

    • 4.6 Osmotic Agents/Diuretics

      • 4.6.1 Key market trends, growth factors and opportunities

      • 4.6.2 Market size and forecast, by region

      • 4.6.3 Market analysis by country

    • 4.7 Other Drugs

      • 4.7.1 Key market trends, growth factors and opportunities

      • 4.7.2 Market size and forecast, by region

      • 4.7.3 Market analysis by country

  • CHAPTER 5: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY REGION

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 North America

      • 5.2.1 Key trends and opportunities

      • 5.2.2 North America Market size and forecast, by Drug Class

      • 5.2.3 North America Market size and forecast, by country

        • 5.2.3.1 U.S.
          • 5.2.3.1.1 Market size and forecast, by Drug Class
        • 5.2.3.2 Canada
          • 5.2.3.2.1 Market size and forecast, by Drug Class
        • 5.2.3.3 Mexico
          • 5.2.3.3.1 Market size and forecast, by Drug Class

    • 5.3 Europe

      • 5.3.1 Key trends and opportunities

      • 5.3.2 Europe Market size and forecast, by Drug Class

      • 5.3.3 Europe Market size and forecast, by country

        • 5.3.3.1 Germany
          • 5.3.3.1.1 Market size and forecast, by Drug Class
        • 5.3.3.2 France
          • 5.3.3.2.1 Market size and forecast, by Drug Class
        • 5.3.3.3 United Kingdom
          • 5.3.3.3.1 Market size and forecast, by Drug Class
        • 5.3.3.4 Italy
          • 5.3.3.4.1 Market size and forecast, by Drug Class
        • 5.3.3.5 Rest of Europe
          • 5.3.3.5.1 Market size and forecast, by Drug Class

    • 5.4 Asia-Pacific

      • 5.4.1 Key trends and opportunities

      • 5.4.2 Asia-Pacific Market size and forecast, by Drug Class

      • 5.4.3 Asia-Pacific Market size and forecast, by country

        • 5.4.3.1 Japan
          • 5.4.3.1.1 Market size and forecast, by Drug Class
        • 5.4.3.2 China
          • 5.4.3.2.1 Market size and forecast, by Drug Class
        • 5.4.3.3 Australia
          • 5.4.3.3.1 Market size and forecast, by Drug Class
        • 5.4.3.4 India
          • 5.4.3.4.1 Market size and forecast, by Drug Class
        • 5.4.3.5 Rest of Asia-Pacific
          • 5.4.3.5.1 Market size and forecast, by Drug Class

    • 5.5 LAMEA

      • 5.5.1 Key trends and opportunities

      • 5.5.2 LAMEA Market size and forecast, by Drug Class

      • 5.5.3 LAMEA Market size and forecast, by country

        • 5.5.3.1 Brazil
          • 5.5.3.1.1 Market size and forecast, by Drug Class
        • 5.5.3.2 Turkey
          • 5.5.3.2.1 Market size and forecast, by Drug Class
        • 5.5.3.3 South Africa
          • 5.5.3.3.1 Market size and forecast, by Drug Class
        • 5.5.3.4 Rest of LAMEA
          • 5.5.3.4.1 Market size and forecast, by Drug Class

  • CHAPTER 6: COMPANY LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top winning strategies

    • 6.3. Product Mapping of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Key developments

  • CHAPTER 7: COMPANY PROFILES

    • 7.1 Azurity Pharmaceuticals

      • 7.1.1 Company overview

      • 7.1.2 Company snapshot

      • 7.1.3 Operating business segments

      • 7.1.4 Product portfolio

      • 7.1.5 Business performance

      • 7.1.6 Key strategic moves and developments

    • 7.2 Johnson and Johnson

      • 7.2.1 Company overview

      • 7.2.2 Company snapshot

      • 7.2.3 Operating business segments

      • 7.2.4 Product portfolio

      • 7.2.5 Business performance

      • 7.2.6 Key strategic moves and developments

    • 7.3 medicure

      • 7.3.1 Company overview

      • 7.3.2 Company snapshot

      • 7.3.3 Operating business segments

      • 7.3.4 Product portfolio

      • 7.3.5 Business performance

      • 7.3.6 Key strategic moves and developments

    • 7.4 NeurOp

      • 7.4.1 Company overview

      • 7.4.2 Company snapshot

      • 7.4.3 Operating business segments

      • 7.4.4 Product portfolio

      • 7.4.5 Business performance

      • 7.4.6 Key strategic moves and developments

    • 7.5 orexo ab

      • 7.5.1 Company overview

      • 7.5.2 Company snapshot

      • 7.5.3 Operating business segments

      • 7.5.4 Product portfolio

      • 7.5.5 Business performance

      • 7.5.6 Key strategic moves and developments

    • 7.6 Pfizer, Inc.

      • 7.6.1 Company overview

      • 7.6.2 Company snapshot

      • 7.6.3 Operating business segments

      • 7.6.4 Product portfolio

      • 7.6.5 Business performance

      • 7.6.6 Key strategic moves and developments

    • 7.7 Pharmaxis, Ltd.

      • 7.7.1 Company overview

      • 7.7.2 Company snapshot

      • 7.7.3 Operating business segments

      • 7.7.4 Product portfolio

      • 7.7.5 Business performance

      • 7.7.6 Key strategic moves and developments

    • 7.8 Sun Pharmaceutical Industries Ltd.

      • 7.8.1 Company overview

      • 7.8.2 Company snapshot

      • 7.8.3 Operating business segments

      • 7.8.4 Product portfolio

      • 7.8.5 Business performance

      • 7.8.6 Key strategic moves and developments

    • 7.9 teva pharmaceutical industries ltd.

      • 7.9.1 Company overview

      • 7.9.2 Company snapshot

      • 7.9.3 Operating business segments

      • 7.9.4 Product portfolio

      • 7.9.5 Business performance

      • 7.9.6 Key strategic moves and developments

    • 7.10 Vitrais, Inc

      • 7.10.1 Company overview

      • 7.10.2 Company snapshot

      • 7.10.3 Operating business segments

      • 7.10.4 Product portfolio

      • 7.10.5 Business performance

      • 7.10.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
    TABLE 2. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR OPIOID ANALGESIC, BY REGION , 2020-2030,($MILLION)
    TABLE 3. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET OPIOID ANALGESIC BY COUNTRY, 2020-2030,($MILLION)
    TABLE 4. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR CALCIUM CHANNEL BLOCKER, BY REGION , 2020-2030,($MILLION)
    TABLE 5. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET CALCIUM CHANNEL BLOCKER BY COUNTRY, 2020-2030,($MILLION)
    TABLE 6. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR ANTICONVULSANT, BY REGION , 2020-2030,($MILLION)
    TABLE 7. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET ANTICONVULSANT BY COUNTRY, 2020-2030,($MILLION)
    TABLE 8. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR STOOL SOFTENER, BY REGION , 2020-2030,($MILLION)
    TABLE 9. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET STOOL SOFTENER BY COUNTRY, 2020-2030,($MILLION)
    TABLE 10. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR OSMOTIC AGENTS/DIURETICS, BY REGION , 2020-2030,($MILLION)
    TABLE 11. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET OSMOTIC AGENTS/DIURETICS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 12. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR OTHER DRUGS, BY REGION , 2020-2030,($MILLION)
    TABLE 13. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET OTHER DRUGS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 14. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY REGION, 2020-2030,($MILLION)
    TABLE 15. NORTH AMERICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
    TABLE 16. NORTH AMERICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 17. U.S. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 18. CANADA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 19. MEXICO ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 20. EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
    TABLE 21. EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 22. GERMANY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 23. FRANCE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 24. UNITED KINGDOM ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 25. ITALY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 26. REST OF EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 27. ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
    TABLE 28. ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 29. JAPAN ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 30. CHINA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 31. AUSTRALIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 32. INDIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 33. REST OF ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 34. LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
    TABLE 35. LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 36. BRAZIL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 37. TURKEY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 38. SOUTH AFRICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 39. REST OF LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
    TABLE 40.AZURITY PHARMACEUTICALS: COMPANY SNAPSHOT
    TABLE 41.AZURITY PHARMACEUTICALS: OPERATING SEGMENTS
    TABLE 42.AZURITY PHARMACEUTICALS: PRODUCT PORTFOLIO
    TABLE 43.AZURITY PHARMACEUTICALS: NET SALES,
    TABLE 44.AZURITY PHARMACEUTICALS: KEY STRATERGIES
    TABLE 45.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
    TABLE 46.JOHNSON AND JOHNSON: OPERATING SEGMENTS
    TABLE 47.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
    TABLE 48.JOHNSON AND JOHNSON: NET SALES,
    TABLE 49.JOHNSON AND JOHNSON: KEY STRATERGIES
    TABLE 50.MEDICURE: COMPANY SNAPSHOT
    TABLE 51.MEDICURE: OPERATING SEGMENTS
    TABLE 52.MEDICURE: PRODUCT PORTFOLIO
    TABLE 53.MEDICURE: NET SALES,
    TABLE 54.MEDICURE: KEY STRATERGIES
    TABLE 55.NEUROP: COMPANY SNAPSHOT
    TABLE 56.NEUROP: OPERATING SEGMENTS
    TABLE 57.NEUROP: PRODUCT PORTFOLIO
    TABLE 58.NEUROP: NET SALES,
    TABLE 59.NEUROP: KEY STRATERGIES
    TABLE 60.OREXO AB: COMPANY SNAPSHOT
    TABLE 61.OREXO AB: OPERATING SEGMENTS
    TABLE 62.OREXO AB: PRODUCT PORTFOLIO
    TABLE 63.OREXO AB: NET SALES,
    TABLE 64.OREXO AB: KEY STRATERGIES
    TABLE 65.PFIZER, INC.: COMPANY SNAPSHOT
    TABLE 66.PFIZER, INC.: OPERATING SEGMENTS
    TABLE 67.PFIZER, INC.: PRODUCT PORTFOLIO
    TABLE 68.PFIZER, INC.: NET SALES,
    TABLE 69.PFIZER, INC.: KEY STRATERGIES
    TABLE 70.PHARMAXIS, LTD.: COMPANY SNAPSHOT
    TABLE 71.PHARMAXIS, LTD.: OPERATING SEGMENTS
    TABLE 72.PHARMAXIS, LTD.: PRODUCT PORTFOLIO
    TABLE 73.PHARMAXIS, LTD.: NET SALES,
    TABLE 74.PHARMAXIS, LTD.: KEY STRATERGIES
    TABLE 75.SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
    TABLE 76.SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
    TABLE 77.SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
    TABLE 78.SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
    TABLE 79.SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
    TABLE 80.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
    TABLE 81.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
    TABLE 82.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
    TABLE 83.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
    TABLE 84.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
    TABLE 85.VITRAIS, INC: COMPANY SNAPSHOT
    TABLE 86.VITRAIS, INC: OPERATING SEGMENTS
    TABLE 87.VITRAIS, INC: PRODUCT PORTFOLIO
    TABLE 88.VITRAIS, INC: NET SALES,
    TABLE 89.VITRAIS, INC: KEY STRATERGIES

  • LIST OF FIGURES

  • FIGURE 1.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET SEGMENTATION
    FIGURE 2.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030
    FIGURE 3.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 11.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,BY DRUG CLASS,2020(%)
    FIGURE 12.COMPARATIVE SHARE ANALYSIS OF OPIOID ANALGESIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CALCIUM CHANNEL BLOCKER ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANTICONVULSANT ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF STOOL SOFTENER ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OSMOTIC AGENTS/DIURETICS ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHER DRUGS ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
    FIGURE 18.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY REGION,2020
    FIGURE 19.U.S. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 20.CANADA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 21.MEXICO ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 22.GERMANY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 23.FRANCE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 24.UNITED KINGDOM ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 25.ITALY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 26.REST OF EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 27.JAPAN ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 28.CHINA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 29.AUSTRALIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 30.INDIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 31.REST OF ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 32.BRAZIL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 33.TURKEY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 34.SOUTH AFRICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 35.REST OF LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
    FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 39.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 40.COMPETITIVE DASHBOARD
    FIGURE 41.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 42.AZURITY PHARMACEUTICALS.: NET SALES ,($MILLION)
    FIGURE 43.JOHNSON AND JOHNSON.: NET SALES ,($MILLION)
    FIGURE 44.MEDICURE.: NET SALES ,($MILLION)
    FIGURE 45.NEUROP.: NET SALES ,($MILLION)
    FIGURE 46.OREXO AB.: NET SALES ,($MILLION)
    FIGURE 47.PFIZER, INC..: NET SALES ,($MILLION)
    FIGURE 48.PHARMAXIS, LTD..: NET SALES ,($MILLION)
    FIGURE 49.SUN PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)
    FIGURE 50.TEVA PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)
    FIGURE 51.VITRAIS, INC.: NET SALES ,($MILLION)

 
 

According to the analyst’s perspective, diseases such as hypertension and stroke constitute major proportion of health and economic concern across the globe; hence, the development of effective medication is the major necessity for their treatment.

The major factors that contribute to the market growth include change in lifestyle and rise in geriatric population. In addition, lifestyle changes that include surge in alcohol consumption and smoking rise the risk for aSAH, which accelerate the market growth. Along with this, surge in geriatric population are also prevailing the growth of the aneurysmal subarachnoid hemorrhage drugs market. However, associated side effects of the drugs are expected to restrain the market growth. In addition, need to create awareness about the optimal diagnosis and treatment of aneurysmal subarachnoid hemorrhage is expected to provide lucrative opportunities for the market growth.

North America is anticipated to dominate the aneurysmal subarachnoid hemorrhage drugs market throughout the forecast period, owing to increase in incidence of people suffering from hypertension, followed by Europe and Asia-Pacific.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The Aneurysmal Subarachnoid Hemorrhage Market is currently growing at a CAGR of 3.6% from 2021-2030.

A. Drug types such as Opioid Analgesic, Calcium Channel Blocker, Anticonvulsant, Stool Softener, Osmotic Agents/Diuretics which are off label drugs are used in treating Aneurysmal Subarachnoid Hemorrhage.

A. Estimated industry size of Aneurysmal Subarachnoid Hemorrhage Drugs Market is USD 323.5 Million in 2020

A. Largest regional market for Aneurysmal Subarachnoid Hemorrhage Drugs Market is North America.

A. Azurity Pharmaceuticals, Johnson and Johnson, MediCure, NeurOp, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Aneurysmal Subarachnoid Hemorrhage Drugs Market

Start reading instantly.
This Report and over 66,782+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Mar 2023 - Mar 2024)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2023 - Mar 2024)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2023 - Mar 2024)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2023 - Mar 2024)

  • Enterprise
    License/PDF

  • $10,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2023 - Mar 2024)

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers